FABBRI, MARIA AGNESE
 Distribuzione geografica
Continente #
NA - Nord America 259
EU - Europa 91
AS - Asia 9
AF - Africa 3
SA - Sud America 1
Totale 363
Nazione #
US - Stati Uniti d'America 255
IT - Italia 39
FR - Francia 22
DE - Germania 13
CN - Cina 6
SE - Svezia 6
CA - Canada 4
FI - Finlandia 4
CH - Svizzera 3
ZA - Sudafrica 3
SA - Arabia Saudita 2
UA - Ucraina 2
BE - Belgio 1
CL - Cile 1
IN - India 1
RU - Federazione Russa 1
Totale 363
Città #
Santa Cruz 32
Seattle 28
Fairfield 27
Rome 25
Buffalo 21
Ashburn 18
Woodbridge 18
Cambridge 14
Houston 11
Wilmington 7
Stockholm 6
Bremen 5
Boardman 4
Des Moines 4
Phoenix 4
Wuhan 4
Chicago 3
Helsinki 3
Los Angeles 3
Muizenberg 3
Clearwater 2
Frankfurt am Main 2
Guangzhou 2
Ottawa 2
San Francisco 2
Toronto 2
Ann Arbor 1
Atlanta 1
Brooklyn 1
Cheyenne 1
Columbus 1
Dallas 1
Falkenstein 1
Gunzenhausen 1
Kirkland 1
Kraainem 1
Lake Forest 1
Las Vegas 1
Laurel 1
Levallois-perret 1
Mainz 1
Pune 1
Reston 1
Riva 1
San Diego 1
San Mateo 1
Scranton 1
Secaucus 1
Totale 274
Nome #
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study, file e3835321-b842-15e8-e053-a505fe0a3de9 110
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab, file e3835323-37d4-15e8-e053-a505fe0a3de9 90
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer. Potential molecular mechanisms, clinical implications and future perspectives, file e383532a-18d9-15e8-e053-a505fe0a3de9 77
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting, file e3835322-d440-15e8-e053-a505fe0a3de9 59
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting, file e383532e-fa2b-15e8-e053-a505fe0a3de9 15
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial, file 414ca0a4-8e30-4a18-94ef-25ad85b00f14 11
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting, file e383532a-6618-15e8-e053-a505fe0a3de9 10
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients. A multicenter Italian experience, file e3835321-705d-15e8-e053-a505fe0a3de9 8
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study, file 9dc11e0f-7d44-475a-8534-d3594138c914 1
Totale 381
Categoria #
all - tutte 811
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 811


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201912 0 0 0 0 0 0 0 0 0 0 2 10
2019/202066 3 2 4 2 12 7 10 6 8 4 5 3
2020/202174 10 0 4 7 0 8 1 3 6 24 8 3
2021/202298 3 9 6 1 12 4 7 2 8 5 30 11
2022/202390 10 1 21 21 5 8 7 4 5 0 8 0
2023/202441 2 0 2 2 8 9 7 8 3 0 0 0
Totale 381